LL-37: Best Telehealth Providers for Healing & Tissue Regeneration (2026)
The only known human cathelicidin antimicrobial peptide, naturally produced by immune cells and epithelial tissues. LL-37 has broad-spectrum antimicrobial activity alongside potent immunomodulatory and wound-healing properties.
Reviewed by Dr. James Okafor, PharmDPharmDLL-37 at a Glance
Category
Healing & Tissue Regeneration
Administration
Topical or subcutaneous injection
Telehealth Providers
3 compared
Price Range
$50 – $240/mo
Typical Dose
100-200mcg
Frequency
2-3 times weekly
Protocol Duration
4-12 weeks
Prescription
Required
Research highlight: LL-37 is the only known human cathelicidin antimicrobial peptide, exhibiting broad-spectrum antimicrobial activity against bacteria, viruses, and fungi plus unique anti-biofilm properties against antibiotic-resistant organisms like MRSA and VRE.
What is LL-37 Used For?
Also known as: Cathelicidin, hCAP18/LL-37
- Antimicrobial defense
- Chronic wound healing
- Immune modulation
- Skin repair
How LL-37 Works
LL-37 is the only known member of the cathelicidin family of antimicrobial peptides in humans. It is produced by neutrophils, macrophages, and epithelial cells as a broad-spectrum antimicrobial defense — disrupting bacterial cell membranes through electrostatic interaction and pore formation. Beyond its antimicrobial function, LL-37 is a potent immunomodulator: it activates innate immune receptors (TLR4, FPRL1), promotes wound healing through growth factor-like signaling, and exhibits anti-biofilm activity against resistant organisms.
LL-37Dosing & Administration
| Typical Dose | 100-200mcg |
| Frequency | 2-3 times weekly |
| Protocol Duration | 4-12 weeks |
| Route | Topical or subcutaneous injection |
Dosing information is for educational purposes only. Your prescribing physician will determine the appropriate dose based on your medical history and treatment goals.
What to Expect from LL-37
For chronic wound healing, improvements in wound tissue granulation and epithelialization are typically reported within 2–4 weeks of topical or local injection. Systemic immune effects from subcutaneous injection vary by indication — chronic infection management protocols typically run 4–12 weeks. The antimicrobial effects are most pronounced in local tissue application.
Who Should Consider LL-37?
- Chronic wounds with poor healing response
- Antibiotic-resistant infections (MRSA, VRE)
- Biofilm-associated infections
- Immune support and innate immune system enhancement
LL-37 Side Effects
- Topical: mild burning or stinging at application site
- Systemic: mild injection site reactions
- Temporary inflammatory response at high local concentrations
- Generally well-tolerated in clinical studies
This is not a complete list of side effects. Always consult your prescribing physician before starting LL-37.
3 Telehealth Providers Offering LL-37
Sorted by lowest price. All providers require a prescription from a licensed physician.
| Provider | Price | Dose | Rating | Consultation | Lab Testing |
|---|---|---|---|---|---|
| Amino Asylum United States | $50/one-time | 5mg vial | 3.8/5 | Async Telehealth | Not included |
| Defy Medical Tampa, FL | $180/monthly | Standard protocol | 4.1/5 | Video Telehealth | Included |
| TruLife Health Scottsdale, AZ | $240/monthly | Standard protocol | 4.1/5 | Video Telehealth | Included |
How to Choose the Best Telehealth Provider for Healing Peptides
Healing peptide protocols require clinical precision. These are the criteria that separate excellent providers from those cutting corners.
Injury-Specific Protocol Design
The best providers tailor peptide selection, dosing, and stacking to your specific injury type — gut healing, tendon repair, and post-surgical recovery each require different approaches.
503A/503B Pharmacy Sourcing
Healing peptides like BPC-157 and TB-500 must come from FDA-registered compounding pharmacies. Verify your provider uses a licensed 503A or 503B facility — product quality directly affects outcomes.
Imaging and Diagnostics Integration
Providers who request imaging (MRI, ultrasound) or lab work before prescribing can make better-informed decisions about protocol design, dosing, and duration.
Progress Monitoring
Healing protocols should include structured follow-ups to assess tissue response, adjust dosing, and decide when to cycle off. Providers who prescribe without follow-up leave outcomes to chance.
Stacking Expertise
Many healing peptides work synergistically (BPC-157 + TB-500, KPV + BPC-157 for gut). Providers experienced with peptide stacking can design protocols that address multiple healing pathways simultaneously.
Regulatory Awareness
FDA restrictions on certain peptides (BPC-157 bulk compounding) mean availability shifts. The best providers stay current and offer compliant alternatives (Pentadeca Arginate) when needed.
Frequently Asked Questions About LL-37
Can LL-37 treat antibiotic-resistant infections?
LL-37's mechanism of action (membrane disruption) is fundamentally different from conventional antibiotics, meaning bacterial resistance mechanisms (enzyme degradation, efflux pumps) do not apply in the same way. Research shows activity against MRSA, VRE, and drug-resistant gram-negative organisms. Clinical evidence is still building, but LL-37 is promising for antibiotic-resistant biofilm infections.
Is LL-37 used for skin conditions?
Yes — LL-37 is naturally elevated in psoriatic skin and plays a role in the skin's innate immune response. Topical LL-37 is studied for wound healing, eczema, rosacea, and acne. Paradoxically, elevated LL-37 in psoriasis can trigger autoimmune DNA sensing — topical therapeutic use focuses on wound healing rather than psoriasis.
Does LL-37 have anti-cancer properties?
Research is mixed. LL-37 shows anti-cancer activity in some cancer models (ovarian, lung, gastric) but pro-cancer activity in others (breast cancer cells). This context-dependence means LL-37 should not be used as a cancer treatment and should be avoided in patients with active malignancy until its role in specific cancer types is better characterized.
How does LL-37 compare to silver or hypochlorous acid for wound care?
Silver and hypochlorous acid are broad-spectrum antimicrobial wound care agents that work through oxidative mechanisms. LL-37 adds immunomodulatory, wound-healing-promoting, and anti-biofilm properties beyond simple antimicrobial action. It is most valuable in wounds complicated by infection, poor healing response, or biofilm formation where standard antimicrobials are insufficient.
LL-37 Alternatives for Healing & Tissue Regeneration
Compare other healing & tissue regeneration peptides available through telehealth.
BPC-157
A synthetic peptide derived from a protective protein found in human gastric juice. Widely studied for its regenerative properties on tendons, ligaments, muscles, and the gut lining.
GHK-Cu
A naturally occurring copper-binding peptide found in human plasma. Declines with age and is used therapeutically for skin rejuvenation, wound healing, and anti-inflammatory effects.
KPV
A tripeptide fragment derived from the C-terminus of alpha-melanocyte-stimulating hormone (α-MSH). KPV carries the anti-inflammatory properties of α-MSH without its melanogenic effects, making it a targeted tool for gut and systemic inflammation.
Pentadeca Arginate
A stable arginate salt form of a 15-amino-acid sequence related to BPC-157. Developed as a compounding-pharmacy-compatible alternative following FDA regulatory pressure on BPC-157. Offers similar regenerative and anti-inflammatory benefits through overlapping pathways.
TB-500
A synthetic fragment of thymosin beta-4, a naturally occurring peptide involved in tissue repair and regeneration. Studied for its ability to promote healing of muscles, tendons, ligaments, and skin.